Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients.
Non-exclusivelicense agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies Collaboration aims to combine best-in-class PCIOL optics with first ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
MarketBeat on MSN
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook
Key Points Interested in RxSight, Inc.? Here are five stocks we like better. RxSight's preliminary Q2 sales fell 20% year over year to about $27 million excluding collaboration revenue, with Light ...
Despite near-term headwinds, RxSight has long-term upside from the Alcon royalty partnership, stronger margins and discounted ...
RxSight’s (RXST) innovative product – the RxSight Light Adjustable Lens (‘LAL’) system was launched in the United States in 2020 and it was able to capture 5% of the premium intraocular lens (‘IOL’) ...
RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates ...
Please provide your email address to receive an email when new articles are posted on . The lens will combine light-adjustable technology from RxSight with optical designs from Alcon. RxSight will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results